TABLE OF CONTENTS
EXECUTIVE SUMMARY 2
MARKET OVERVIEW 7
Market definition 7
Research highlights 8
Market analysis 9
MARKET VALUE 10
MARKET SEGMENTATION I 11
MARKET SEGMENTATION II 12
MARKET SHARE 13
FIVE FORCES ANALYSIS 14
Summary 14
Buyer power 16
Supplier power 17
New entrants 18
Substitutes 20
Rivalry 21
LEADING COMPANIES 22
Johnson & Johnson 22
Novartis AG 27
GlaxoSmithKline Plc 31
MARKET DISTRIBUTION 36
MARKET FORECASTS 37
Market value forecast 37
MACROECONOMIC INDICATORS 38
APPENDIX 40
Methodology 40
Industry associations 41
Related Datamonitor research 41
Disclaimer 43
ABOUT DATAMONITOR 44
Premium Reports 44
Summary Reports 44
Datamonitor consulting 44
LIST OF TABLES
Table 1: Norway OTC pharmaceuticals market value: $ million, 2005–09 10
Table 2: Norway OTC pharmaceuticals market segmentation I:% share, by value, 2009 11
Table 3: Norway OTC pharmaceuticals market segmentation II: % share, by value, 2009 12
Table 4: Norway OTC pharmaceuticals market share: % share, by value, 2009 13
Table 5: Johnson & Johnson: key facts 22
Table 6: Johnson & Johnson: key financials ($) 24
Table 7: Johnson & Johnson: key financial ratios 25
Table 8: Novartis AG: key facts 27
Table 9: Novartis AG: key financials ($) 29
Table 10: Novartis AG: key financial ratios 29
Table 11: GlaxoSmithKline Plc: key facts 31
Table 12: GlaxoSmithKline Plc: key financials ($) 33
Table 13: GlaxoSmithKline Plc: key financials (£) 34
Table 14: GlaxoSmithKline Plc: key financial ratios 34
Table 15: Norway OTC pharmaceuticals market distribution: % share, by value, 2009 36
Table 16: Norway OTC pharmaceuticals market value forecast: $ million, 2009–14 37
Table 17: Norway size of population (million), 2005–09 38
Table 18: Norway gdp (constant 2000 prices, $ billion), 2005–09 38
Table 19: Norway gdp (current prices, $ billion), 2005–09 38
Table 20: Norway inflation, 2005–09 39
Table 21: Norway consumer price index (absolute), 2005–09 39
Table 22: Norway exchange rate, 2005–09 39
LIST OF FIGURES
Figure 1: Norway OTC pharmaceuticals market value: $ million, 2005–09 10
Figure 2: Norway OTC pharmaceuticals market segmentation I:% share, by value, 2009 11
Figure 3: Norway OTC pharmaceuticals market segmentation II: % share, by value, 2009 12
Figure 4: Norway OTC pharmaceuticals market share: % share, by value, 2009 13
Figure 5: Forces driving competition in the OTC pharmaceuticals market in Norway, 2009 14
Figure 6: Drivers of buyer power in the OTC pharmaceuticals market in Norway, 2009 16
Figure 7: Drivers of supplier power in the OTC pharmaceuticals market in Norway, 2009 17
Figure 8: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Norway, 2009 18
Figure 9: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Norway, 2009 20
Figure 10: Drivers of degree of rivalry in the OTC pharmaceuticals market in Norway, 2009 21
Figure 11: Johnson & Johnson: revenues & profitability 25
Figure 12: Johnson & Johnson: assets & liabilities 26
Figure 13: Novartis AG: revenues & profitability 30
Figure 14: Novartis AG: assets & liabilities 30
Figure 15: GlaxoSmithKline Plc: revenues & profitability 35
Figure 16: GlaxoSmithKline Plc: assets & liabilities 35
Figure 17: Norway OTC pharmaceuticals market distribution: % share, by value, 2009 36
Figure 18: Norway OTC pharmaceuticals market value forecast: $ million, 2009–14 37
[Fade out table of contents]
